What development phase is Norflurazepam in?

Norflurazepam is FDA-approved (marketed).

What is the generic name of Norflurazepam?

desalkylflurazepam is the generic (nonproprietary) name of Norflurazepam.

Last reviewed 2026-04-20 · How we verify

Norflurazepam (desalkylflurazepam)

FDA-approved active Quality 10/100

Desalkylflurazepam (Norflurazepam) is a marketed drug that enhances GABA activity, providing sedative, anxiolytic, and muscle relaxant effects. Its key strength lies in its well-established mechanism and ongoing patent protection until 2028, which helps maintain market exclusivity. The primary risk is the strong competition from off-patent generics like alprazolam and amoxapine, which may erode market share.

At a glance

Generic name	desalkylflurazepam
Drug class	desalkylflurazepam
Target	GABA-A receptor alpha-1/beta-2/gamma-2
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Norflurazepam CI brief — competitive landscape report
Norflurazepam updates RSS · CI watch RSS
portfolio CI